Teva Pharmaceuticals has placed a $125 million opening bid on the most valuable assets of BioXcel Therapeutics, a neuroscience company now working through bankruptcy proceedings in Delaware, and the deal could put a new treatment for acute agitation into millions more hands — or it could get outbid.

BioXcel filed for voluntary Chapter 11 bankruptcy protection and is using a court-supervised auction to sell off its core assets. Teva has stepped in as the "stalking horse bidder," which means it sets the floor price that any competing offer has to beat. If someone else wins, Teva walks away with a break-up fee and expense reimbursement. If Teva wins, it gets worldwide rights to two drugs.

What Teva is actually buying

The first is Igalmi, a prescription film that dissolves under the tongue and is already on the market. It contains dexmedetomidine, a sedative compound used to treat acute agitation in adults with schizophrenia or bipolar disorder. The drug is currently available commercially and will remain so while the bankruptcy process plays out.

The second is BXCL501, an investigational drug currently under review by the FDA for potential at-home use in treating the same kinds of acute agitation. That last part matters: at-home use would be a meaningful shift from the clinical settings where most agitation treatments are currently administered.

The financial structure reflects the uncertainty. Teva pays $57.5 million upfront. The remaining $67.5 million is contingent, meaning it only gets paid if certain milestones are hit, specifically FDA approval timing and sales targets. That structure is standard when a drug is still awaiting regulatory clearance. Teva absorbs less risk if the FDA says no; BioXcel's creditors get more upside if the FDA says yes.

Why this matters beyond the deal itself

Acute agitation is a medical emergency that families and caregivers often handle badly, not because they're careless, but because the tools available have been limited and mostly hospital-bound. Schizophrenia and bipolar disorder together affect roughly 5 to 6 percent of American adults, and agitation episodes can escalate quickly into situations that end with police calls or emergency room visits rather than treatment.

A fast-dissolving film that a caregiver could administer at home, if the FDA approves BXCL501 for that use, would represent a real change in how those crises get managed. Whether Teva is the company to bring that to market depends first on whether it wins the auction, and then on FDA's decision.

Teva's interest here also reflects a broader shift in how large pharmaceutical companies are rebuilding their pipelines. Rather than funding early-stage research from scratch, buying assets out of bankruptcy is increasingly attractive: the science has already been developed, the regulatory path is partially cleared, and the seller's financial distress means the price is lower than it would be in a conventional acquisition. Teva's executive vice-president of business development described the move as part of a "Pivot to Growth strategy," and the structure of this deal, disciplined upfront payment with milestone-linked upside, fits that framing precisely.

The auction process still has to play out. BioXcel has also secured $19 million in short-term financing from existing lenders to keep the lights on while the court process runs. If another bidder tops Teva's offer, the $57.5 million floor will have served its purpose: it got the auction started and guaranteed BioXcel's creditors at least that much. If no better bid materialises, Teva picks up a commercial drug and an FDA-pending candidate for roughly the cost of a mid-sized cable deal.

For patients on Igalmi, nothing changes right now. The drug stays on the market through the proceedings. The question is who controls it six months from now.